#647
Alpha Score 14.1
A May MD
Biotech investor
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
Long
Mar 23
$117.41
-24.5%
ABVX stock sentiment improves after the company hired a high-profile executive to lead commercial efforts.
ABVX stock sentiment improves after the company hired a high-profile executive to lead commercial efforts.
Healthcare
Long
Mar 12
$71.40
-17.0%
Nektar Therapeutics is expected to see positive momentum for its alopecia areata treatment following upcoming data presentations and maintenance updates.
Nektar Therapeutics is expected to see positive momentum for its alopecia areata treatment following upcoming data presentations and maintenance updates.
Healthcare
Long
Mar 24
$36.87
+14.0%
Novo Nordisk is poised for growth due to record-breaking drug adoption and regulatory crackdowns on the illicit market.
Novo Nordisk is poised for growth due to record-breaking drug adoption and regulatory crackdowns on the illicit market.
Healthcare
Short
Apr 27
$13.95
+6.7%
Short $NTLA based on a dilution spiral thesis: the company urgently needs financing, so falling share prices worsen implied dilution, creating a self-reinforcing downside loop.
Short $NTLA based on a dilution spiral thesis: the company urgently needs financing, so falling share prices worsen implied dilution, creating a self-reinforcing downside loop.
Healthcare
Short
Apr 27
$70.00
+18.3%
Short ORKA due to phase 2a data that merely matches existing therapies (Skyrizi, Bimzelx) while facing biosimilar competition and a $7B market cap that implies unjustified premium for a heavily served indication.
Short ORKA due to phase 2a data that merely matches existing therapies (Skyrizi, Bimzelx) while facing biosimilar competition and a $7B market cap that implies unjustified premium for a heavily served indication.
Healthcare
Short
Apr 13
$66.73
-10.2%
Fade SYRE's Phase 2a data release, as the study's open-label design without a placebo group makes the results unreliable compared to established blinded studies.
Fade SYRE's Phase 2a data release, as the study's open-label design without a placebo group makes the results unreliable compared to established blinded studies.
Healthcare
Short
May 13
$24.66
-8.8%
Short HIMS based on speaker’s prior margin compression call being validated by the -14% drop, reinforcing continued bearish thesis.
Short HIMS based on speaker’s prior margin compression call being validated by the -14% drop, reinforcing continued bearish thesis.
Healthcare
Long
Apr 26
$69.03
-17.1%
Buy ORKA ahead of tomorrow's Phase 2a data; speaker expects positive readout on PASI100 response rate based on proven IL23p19 efficacy, though valuation near $5B adds risk.
Buy ORKA ahead of tomorrow's Phase 2a data; speaker expects positive readout on PASI100 response rate based on proven IL23p19 efficacy, though valuation near $5B adds risk.
Healthcare
Long
Apr 24
$13.63
-4.5%
The author expresses strong confidence in upcoming clinical data for NTLA, anticipating positive efficacy and safety results that could serve as a significant catalyst for the stock.
The author expresses strong confidence in upcoming clinical data for NTLA, anticipating positive efficacy and safety results that could serve as a significant catalyst for the stock.
Healthcare
Long
Apr 20
$138.10
-6.0%
Go long biotech as massive cash generation from the GLP-1 boom enables large pharma companies to fund M&A and deals across the broader sector.
Go long biotech as massive cash generation from the GLP-1 boom enables large pharma companies to fund M&A and deals across the broader sector.
Healthcare
Long
Apr 13
$1.87
+3.2%
Buy PALI to exploit a relative value inefficiency, as competitors are gaining multiples of PALI's entire market cap based on inferior open-label clinical data.
Buy PALI to exploit a relative value inefficiency, as competitors are gaining multiples of PALI's entire market cap based on inferior open-label clinical data.
Healthcare
Long
Apr 01
$961.51
+12.6%
The tweet mentions Eli Lilly and Novo Nordisk without providing specific sentiment or context.
Healthcare
Showing 12 of 12 picks · sorted by mentions
Choose a mentions count to open ticker posts.